CClinicalTrials.gg
CompletedNCT02201108TERIKIDSUpdated Feb 6, 2025Results posted

Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis

A Phase 3 interventional study of Teriflunomide and Placebo in Multiple Sclerosis, sponsored by Genzyme, a Sanofi Company. Completed at 57 sites in 22 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Genzyme, a Sanofi Company · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Study summary

Primary Objective:

To assess the effect of teriflunomide in comparison to placebo on disease activity measured by time to first clinical relapse after randomization in children and adolescents 10 to 17 years of age with relapsing forms of multiple sclerosis (MS).

Secondary Objective:

  • To assess the effect of teriflunomide in comparison to placebo on disease activity/progression measured by brain magnetic resonance imaging (MRI) and on cognitive function.
  • To evaluate the safety and tolerability of teriflunomide in comparison to placebo.
  • To evaluate the pharmacokinetics (PK) of teriflunomide.
Read the detailed description

The study duration included a screening period up to 4 weeks, a double-blind treatment period of up to 96 weeks, an open-label period which included the remainder of the initial 96 weeks, where applicable, and a 96-week extension, i.e., up to a maximum of 192 weeks after randomization. There was a follow-up period of 4 weeks for participants discontinuing treatment.

Within the 96 weeks double-blind treatment period, the first 4 weeks were PK run-in phase in which PK samples (blood samples) were collected from participants and then 4 weeks of analysis (no samples drawn). The PK run-in phase (total 8 weeks) was intended to provide individual PK parameters to allow the dose adjustment to the 14 milligrams (mg) adult-equivalent dose for the rest of the study.

Participants who experienced a relapse after the PK run-in phase (8 weeks) and confirmed by the Relapse Adjudication Panel and participants who fulfilled MRI criteria (high number of new lesions at weeks 36, 48 or 72 compared to previous images) had the option to continue in an open-label teriflunomide treatment arm up to 192 weeks from randomization.

An optional additional extension period was available for young participants with teriflunomide until the participants are 18 years old and/or able to switch to commercial product, whichever comes first.

02

Conditions studied

  • Multiple Sclerosis
03

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Participants with relapsing MS were eligible. Participants who met the criteria of MS based on McDonald criteria 2010 and International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS, version of 2012 and had:

    • at least one relapse (or attack) in the 12 months preceding screening or,
    • at least two relapses (or attack) in the 24 months preceding screening.
  • Less than 18 years of age and greater than or equal to (>=) 10 years of age at randomization. Specific for the Russian Federation from 18 December 2014 to 26 July 2016, less than or equal to 17 years of age and >= 13 years of age at randomization.
  • Signed informed consent/assent obtained from participant and participant's legal representative (parents or guardians) according to local regulations.

Exclusion criteria:

  • Expanded disability status scale score greater than 5.5 at screening or randomization visits.
  • Relapse within 30 days prior to randomization.
  • Treated with:

    • glatiramer acetate, interferons, or dimethyl fumarate within 1 month prior to randomization.
    • fingolimod, or intravenous immunoglobulins within 3 months prior to randomization.
    • natalizumab, other immunosuppressant or immunomodulatory agents such as cyclophosphamide, azathioprine, cyclosporine, methotrexate, mycophenolate, within 6 months prior to randomization.
    • cladribine or mitoxantrone within 2 years prior to randomization.
  • Treated with alemtuzumab at any time.
  • History of human immunodeficiency virus infection.
  • Contraindication for MRI.
  • Pregnant or breast-feeding females or those who plan to become pregnant during the study.
  • Female participants of child-bearing potential not using highly effective contraceptive method (contraception in both female and male was required).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo tablets

    Drug: Placebo

  • Experimental
    Teriflunomide

    Teriflunomide oral tablet, three dosages (3.5, 7 or 14 mg) to reach 14 mg adult equivalent

    Drug: Teriflunomide

Interventions

  • DrugTeriflunomide

    Pharmaceutical form:film-coated tablet, Route of administration: oral

    Also known as: AUBAGIO, HMR1726

  • DrugPlacebo

    Pharmaceutical form:tablet, Route of administration: oral

05

What researchers measure

Primary outcomes

  1. Time to First Confirmed Clinical Relapse

    Time to first clinical relapse was defined as the duration (in weeks) between randomization and first confirmed clinical relapse. Clinical relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon neurological examination and documented by a standardized, quantified functional system score (FSSs) which included 8 items and items were rated on different scales: brain stem, cerebellar and cerebral functions rated on a scale of 0 to 5; visual, pyramidal, sensory and bowel/bladder rated on a scale of 0 to 6 and ambulation on a scale of 0 to 12, where higher score in each scale indicated worsened neurological function. Confirmed clinical relapse were reviewed and confirmed by an independent Relapse Adjudication Panel (RAP). A participant without confirmed clinical relapse, was considered as clinical relapse free until the end of Week 96.

    Time frame: Baseline up to Week 96

Secondary outcomes

  1. Probability of Participants Who Were Clinical Relapse Free at Weeks 24, 48, 72, 96, 120, 144, 168 and 192

    Participant was considered free of clinical relapse if the participant had no confirmed clinical relapse before treatment discontinuation/completion in 192 weeks treatment period. Clinical relapses: new/recurrent neurological symptoms not associated with fever/infection, lasted at least 24 hours, and accompanied by new objective neurological findings upon neurological examination and documented by standardized, quantified FSSs which included 8 items: rated on different scales: brain stem, cerebellar and cerebral functions rated on scale of 0 to 5; visual, pyramidal, sensory and bowel/bladder rated on scale of 0 to 6 \& ambulation on scale of 0 to 12, where higher score in each scale indicated worsened neurological function. New/recurrent symptoms occurred less than 30 days following onset of relapse were considered part of same relapse. Probability of participants who were clinical relapse free at specified weeks were estimated by Kaplan-Meier method and reported.

    Time frame: Weeks 24, 48, 72, 96, 120, 144, 168 and 192

  2. Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan

    Number of new or enlarged T2 lesions per scan was defined as the total number of new or enlarged T2 lesion that occurred during the 192 weeks treatment period divided by the total number of scans performed during 192 weeks. To account for the different numbers of scans performed among the participants, a negative binomial regression model with robust variance estimation was used. The model included the total number of new or enlarged T2-lesions as the response variable, with treatment group, region, pubertal status and age as covariates and log-transformed number of scans as an offset variable.

    Time frame: Baseline up to Week 192

  3. Brain Magnetic Resonance Imaging Assessment: Number of T1 Gadolinium (Gd)-Enhancing T1 Lesions Per MRI Scan

    The number of T1 Gd-Enhancing lesions per scan was defined as the total number of Gd-enhancing lesions that occurred during the 192 weeks treatment period divided by the total number of scans performed during 192 weeks. To account for the different number of scans performed among the participants, a negative binomial regression model with robust variance estimation was used. The model included the total number of T1-lesions as the response variable, with treatment group, region, pubertal status and age as covariates and log-transformed number of scans as an offset variable.

    Time frame: Baseline up to Week 192

  4. Brain Magnetic Resonance Imaging Assessment: Change From Baseline in Volume of T2 Lesions at Weeks 24, 36, 48, 72, 96, 144 and 192

    Volume of T2 lesions was measured by MRI scan.

    Time frame: Baseline, DB period: Weeks 24, 36, 48, 72 and 96; OL period: Weeks 48, 96, 144 and 192

  5. Brain Magnetic Resonance Imaging Assessment: Change From Baseline in Volume of T1 Hypointense Lesions

    Volume of T1 hypointense lesions was measured by MRI scan.

    Time frame: Baseline, DB period: Weeks 24, 36, 48, 72 and 96; OL period: Weeks 48, 96, 144 and 192

  6. Brain Magnetic Resonance Imaging Assessment: Number of New T1 Hypointense Lesions Per MRI Scan

    The number of new T1 hypointense lesions were obtained from MRI scans.

    Time frame: Baseline up to Week 192

  7. Brain Magnetic Resonance Imaging Assessment: Percentage of Participants Free of New or Enlarged MRI T2-Lesions

    Percentage of participants who were free of new or enlarged T2 lesions at Weeks 24, 48, 72, 96, 144 and 192 were reported.

    Time frame: Baseline, Weeks 24, 48, 72, 96, 144 and 192

  8. Brain Magnetic Resonance Imaging Assessment: Percent Change From Baseline in Brain Volume at Weeks 24, 36, 48, 72, 96, 144 and 192

    Percent change from baseline in brain volume (assessed using MRI scans of the Brain) at Weeks 24, 36, 48,72, 96, 144 and 192 was reported.

    Time frame: Baseline, DB period: Weeks 24, 36, 48, 72 and 96; OL period: Weeks 48, 96, 144 and 192

  9. Cognitive Assessment: Change From Baseline in Total Number of Correct Substitutions Measured by Symbol Digit Modalities Test (SDMT) at Weeks 24, 48, 72, 96, 120, 144, 168 and 192

    SDMT measures the time to pair abstract symbols with specific numbers. It is a simple substitution task that gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The SDMT score is the number of correct substitution and ranged from 0 (worst outcome) to 110 (best outcome), where higher score indicated better cognitive function.

    Time frame: Baseline, DB period: Weeks 24, 48, 72 and 96; OL period: Weeks 24, 48, 72, 96, 120, 144, 168 and 192

  10. Cognitive Assessment: Change From Baseline in Number of Completed Items Measured by Symbol Digit Modalities Test at Weeks 24, 48, 72, 96, 120, 144, 168 and 192

    SDMT measures the time to pair abstract symbols with specific numbers. It is a simple substitution task that gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The SDMT score is the number of completed items and ranged from 0 (worst outcome) to 110 (best outcome), where higher score indicated better cognitive function.

    Time frame: Baseline, DB period: Weeks 24, 48, 72 and 96; OL period: Weeks 24, 48, 72, 96, 120, 144, 168 and 192

  11. Cognitive Assessment: Change From Baseline in Brief Visuospatial Memory Test-Revised (BVMT-R) Scores at Weeks 96 and 192

    The BVMT consists of three trials in which participants must recall shapes by drawing figures on a blank page (response booklet) after being given the opportunity to memorize the figures (given in BMVT-R form) for 10 seconds. BMVT-R form consists of six figures. Points are awarded based on the accuracy of the drawn figure and by correct placement on the blank page. A minimum of 0 to 12 points/scores are awarded per trial, so a participant can score between 0 and 36 points for all three trials (by adding the points/score from each trial), where higher score indicates better outcome.

    Time frame: Baseline, Weeks 96 and 192

  12. Cognitive Assessment: Change From Baseline in Trail Making Test- Part A (TMT-A) Test Scores (in Seconds) at Week 96 and 192

    'Trail Making Test Part A' is a neuropsychological test of visual attention and task switching. The task requires a participant to 'connect-the-dots' of 25 consecutive numbers (1,2, 3, etc.) in sequential order on a sheet of paper or computer screen. The goal of the participant is to finish the test as quickly as possible, and the time taken to complete the test used as the primary performance metric (in seconds). This is a timed test and the number of seconds to complete the task is recorded. Maximum time allowed is 300 seconds. A lower score indicated better cognitive function.

    Time frame: Baseline, Weeks 96 and 192

  13. Cognitive Assessment: Change From Baseline in Trail Making Test B (TMT-B) Test Scores (in Seconds) at Weeks 96 and 192

    TMT-B is a cognitive test that gives a measure of various aspects of cognitive performance. It is used to measure cognitive fatigue. The test consisted of 25 circles containing 13 sequential numbers (1 to 13) and 12 sequential letters (A to L) positioned. The test evaluates the time (in seconds) to correctly order letters and numbers in alternate order (1, A, 2, B etc.). Maximum time allowed is 300 seconds, where less time/lower score indicated better cognitive function/performance.

    Time frame: Baseline, Weeks 96 and 192

  14. Cognitive Assessment: Change From Baseline in Beery Visual-motor Integration (BVMI) Scores at Weeks 96 and 192

    The Beery VMI is a non-verbal assessment that assessed the extent to which individuals can integrate their visual and motor abilities. The participants were provided with geometric designs ranging from simple line drawings to more complex figures and were asked to copy the designs. The test consisted of 24 figures. One point was scored for each successful copy of drawings and no scoring was given when the participant failed to copy the drawings properly. Each successful copying of drawings was summed up and the total was scored on a scale ranged from 0 to 24, where higher score indicated better visual construction skills/better visual and motor abilities and lower score indicated poor visual construction skills/poor visual and motor abilities.

    Time frame: Baseline, Weeks 96 and 192

  15. Cognitive Assessment: Change From Baseline in Wechsler Abbreviated Scale of Intelligence-II (WASI-II) Vocabulary Total Raw Scores at Weeks 96 and 192

    The WASI-II: Vocabulary test is a quick estimate of an individual's level of intellectual functioning which comprised of 31 total items that required the participant to orally define 3 images and 28 words presented both orally and visually. Items 1 to 3 rated on a score of 0 or 1, items 4 and 5 rated on a score of 0 or 2, items 6 to 31 rated on a scale of 0 to 2. Each item score was summed up to derive the total score which ranged from 0 (minimum score) to 59 (maximum score), where higher score indicated better level of intellectual functioning/higher level of intelligence.

    Time frame: Baseline, Weeks 96 and 192

  16. Cognitive Assessment: Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Letter Fluency Total Correct Raw Score at Weeks 96 and 192

    Letter Fluency is a condition measured in the D-KEFS. Participants were asked to name as many words as they can, starting with a specified letter for 60 seconds. The words cannot be names, places, numbers or grammatical variants of previous answers. Repeated answers were not scored as a correct response. There were 3 trials, with 3 different letters. The total number of correct responses was totaled for all 3 trials and a letter fluency score was given. A higher score was considered better. There was no set range as the score depends on how many correct words the participant relays in the given time period.

    Time frame: Baseline, Weeks 96 and 192

  17. Cognitive Assessment: Change From Baseline in Delis-Kaplan Executive Function System Category Fluency Total Correct Raw Score at Weeks 96 and 192

    Category Fluency is a condition measured in the D-KEFS. It measured participant's ability to generate words from three different categories (e.g., fruits, vegetables and animals), within a minute for each category. Total score was number of correct words for each category with no points for repetitions or non-words. Score ranged from 0 to unlimited, where 0 = low score, higher score indicated better performance.

    Time frame: Baseline, Weeks 96 and 192

  18. Cognitive Assessment - Selective Reminding Test (SRT): Change From Baseline in Total Number of Words on Delayed Recall at Weeks 96 and 192

    SRT is a test to assess verbal learning and memory. During the administration of the SRT only the examiner and the participant should be in the testing room. A list of twelve words was read aloud by the examiner at a rate of one word per two seconds. The participant is asked to recall all twelve words after a 30 minute delay. Only the words that were missed on the preceding trial were given in the consecutive trial. The total score represented a sum score of total 6 trials, therefore the score range was from 0 to 72. The lower the score the worse the outcome, higher score indicated better recall.

    Time frame: Baseline, Weeks 96 and 192

  19. DB: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide

    Ctrough was defined as the concentration reached by the drug before the next dose administered. Data for this outcome measure was planned to be collected and analyzed separately for each dose of Teriflunomide. PK samples for teriflunomide 3.5 mg were collected during the first 8 weeks but all participants were switched to teriflunomide 7 mg after Week 8. Hence, plasma concentration of teriflunomide 7 mg and 14 mg were reported.

    Time frame: Predose on Week 36

  20. OL: Time to First Confirmed Clinical Relapse

    Time to first clinical relapse was defined as duration (in weeks) after enrollment in OL period and first confirmed clinical relapse. Clinical relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasted at least 24 hours and accompanied by new objective neurological findings upon neurological examination and documented by standardized, quantified FSSs which included 8 items and items were rated on different scales: brain stem, cerebellar \& cerebral functions rated on scale of 0 to 5; visual, pyramidal, sensory and bowel/bladder rated on scale of 0 to 6 and ambulation on scale of 0 to 12 where higher score in each scale indicated worsened neurological function. Confirmed clinical relapse were reviewed and confirmed by independent RAP. Participant without confirmed clinical relapse, was considered as clinical relapse free until end of Week 192.

    Time frame: Baseline up to Week 192

  21. OL: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide

    Ctrough was defined as the concentration reached by the drug before the next dose is administered. Data for this outcome measure was planned to be collected and analyzed separately for each dose of teriflunomide. PK samples for teriflunomide 3.5 mg were collected during the first 8 weeks but all participants were switched to teriflunomide 7 mg after Week 8. Hence, plasma concentration of teriflunomide 7 mg and 14 mg were reported.

    Time frame: Pre-dose at Week 36

06

Results

Posted Nov 30, 2020

Participant flow

Study was conducted at 57 active centers in 21 countries. A total of 185 participants were screened between 16 July 2014 and 27 December 2017, of which 166 participants were enrolled and randomized. A total of 19 participants failed screening mainly due to meeting exclusion criteria.

Double-blind Period (up to Week 96)
Participant flow — Double-blind Period (up to Week 96)
MilestonePlacebo/TeriflunomideTeriflunomide/TeriflunomideTeriflunomide
Started571090
Completed531020
Not completed470
Withdrew: Adverse event060
Withdrew: Lack of efficacy210
Withdrew: Withdrawal by subject200
Open Label Period (up to Week 192)
Participant flow — Open Label Period (up to Week 192)
MilestonePlacebo/TeriflunomideTeriflunomide/TeriflunomideTeriflunomide
Started521000
Completed31730
Not completed21270
Withdrew: Lack of efficacy10140
Withdrew: Poor compliance to protocol010
Withdrew: Other reason470
Withdrew: Adverse event750
Extension Period (Up to Week 492)
Participant flow — Extension Period (Up to Week 492)
MilestonePlacebo/TeriflunomideTeriflunomide/TeriflunomideTeriflunomide
Started0027
Completed0024
Not completed003
Withdrew: Adverse event002
Withdrew: Poor compliance to protocol001

Outcome measures

PrimaryTime to First Confirmed Clinical Relapse

Time to first clinical relapse was defined as the duration (in weeks) between randomization and first confirmed clinical relapse. Clinical relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon neurological examination and documented by a standardized, quantified functional system score (FSSs) which included 8 items and items were rated on different scales: brain stem, cerebellar and cerebral functions rated on a scale of 0 to 5; visual, pyramidal, sensory and bowel/bladder rated on a scale of 0 to 6 and ambulation on a scale of 0 to 12, where higher score in each scale indicated worsened neurological function. Confirmed clinical relapse were reviewed and confirmed by an independent Relapse Adjudication Panel (RAP). A participant without confirmed clinical relapse, was considered as clinical relapse free until the end of Week 96.

Time frame:
Baseline up to Week 96
Reported as:
Median · weeks
Time to First Confirmed Clinical Relapse
weeksDouble-Blind Treatment Period: PlaceboDouble-Blind Treatment Period: Teriflunomide
Time to First Confirmed Clinical Relapse39.14 (0.1 to 98.0)75.29 (0.1 to 98.7)
Statistical analysis
  • Double-Blind Treatment Period: Placebo vs Double-Blind Treatment Period: Teriflunomide · Stratified Log-Rank test · p = 0.2949 (Threshold for significance was \< 0.05.) · Hazard ratio (hr): 0.657 · 95% CI 0.388 to 1.113Hazard ratio was estimated using a Cox proportional-hazards model with factors for treatment group, region, pubertal status, age, and number of relapses in the year prior to randomization as covariates and with robust variance estimation.
SecondaryProbability of Participants Who Were Clinical Relapse Free at Weeks 24, 48, 72, 96, 120, 144, 168 and 192

Participant was considered free of clinical relapse if the participant had no confirmed clinical relapse before treatment discontinuation/completion in 192 weeks treatment period. Clinical relapses: new/recurrent neurological symptoms not associated with fever/infection, lasted at least 24 hours, and accompanied by new objective neurological findings upon neurological examination and documented by standardized, quantified FSSs which included 8 items: rated on different scales: brain stem, cerebellar and cerebral functions rated on scale of 0 to 5; visual, pyramidal, sensory and bowel/bladder rated on scale of 0 to 6 \& ambulation on scale of 0 to 12, where higher score in each scale indicated worsened neurological function. New/recurrent symptoms occurred less than 30 days following onset of relapse were considered part of same relapse. Probability of participants who were clinical relapse free at specified weeks were estimated by Kaplan-Meier method and reported.

Time frame:
Weeks 24, 48, 72, 96, 120, 144, 168 and 192
Reported as:
Number · probability of relapse free participants
Probability of Participants Who Were Clinical Relapse Free at Weeks 24, 48, 72, 96, 120, 144, 168 and 192
probability of relapse free participantsPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Week 240.750 (0.609 to 0.846)0.820 (0.730 to 0.883)
Week 480.596 (0.451 to 0.715)0.700 (0.600 to 0.780)
Week 720.519 (0.377 to 0.644)0.630 (0.528 to 0.716)
Week 960.442 (0.305 to 0.571)0.600 (0.497 to 0.688)
Week 1200.404 (0.271 to 0.533)0.570 (0.467 to 0.660)
Week 1440.365 (0.238 to 0.494)0.540 (0.437 to 0.631)
Week 1680.365 (0.238 to 0.494)0.518 (0.416 to 0.611)
Week 1920.365 (0.238 to 0.494)0.518 (0.416 to 0.611)
SecondaryBrain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan

Number of new or enlarged T2 lesions per scan was defined as the total number of new or enlarged T2 lesion that occurred during the 192 weeks treatment period divided by the total number of scans performed during 192 weeks. To account for the different numbers of scans performed among the participants, a negative binomial regression model with robust variance estimation was used. The model included the total number of new or enlarged T2-lesions as the response variable, with treatment group, region, pubertal status and age as covariates and log-transformed number of scans as an offset variable.

Time frame:
Baseline up to Week 192
Reported as:
Number · lesions per scan
Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan
lesions per scanPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Brain Magnetic Resonance Imaging (MRI) Assessment: Number of New or Enlarged T2 Lesions Per MRI Scan11.087 (6.586 to 18.662)5.664 (3.417 to 9.389)
Statistical analysis
  • Placebo/Teriflunomide vs Teriflunomide/ Teriflunomide · Relative risk ratio: 0.511 · 95% CI 0.343 to 0.762
SecondaryBrain Magnetic Resonance Imaging Assessment: Number of T1 Gadolinium (Gd)-Enhancing T1 Lesions Per MRI Scan

The number of T1 Gd-Enhancing lesions per scan was defined as the total number of Gd-enhancing lesions that occurred during the 192 weeks treatment period divided by the total number of scans performed during 192 weeks. To account for the different number of scans performed among the participants, a negative binomial regression model with robust variance estimation was used. The model included the total number of T1-lesions as the response variable, with treatment group, region, pubertal status and age as covariates and log-transformed number of scans as an offset variable.

Time frame:
Baseline up to Week 192
Reported as:
Number · lesions per scan
Brain Magnetic Resonance Imaging Assessment: Number of T1 Gadolinium (Gd)-Enhancing T1 Lesions Per MRI Scan
lesions per scanPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Brain Magnetic Resonance Imaging Assessment: Number of T1 Gadolinium (Gd)-Enhancing T1 Lesions Per MRI Scan2.686 (1.263 to 5.712)1.532 (0.624 to 3.762)
Statistical analysis
  • Placebo/Teriflunomide vs Teriflunomide/ Teriflunomide · Relative risk ratio: 0.57 · 95% CI 0.331 to 0.983
SecondaryBrain Magnetic Resonance Imaging Assessment: Change From Baseline in Volume of T2 Lesions at Weeks 24, 36, 48, 72, 96, 144 and 192

Volume of T2 lesions was measured by MRI scan.

Time frame:
Baseline, DB period: Weeks 24, 36, 48, 72 and 96; OL period: Weeks 48, 96, 144 and 192
Reported as:
Mean · milliliters
Brain Magnetic Resonance Imaging Assessment: Change From Baseline in Volume of T2 Lesions at Weeks 24, 36, 48, 72, 96, 144 and 192
millilitersPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
DB Period: Week 243.0 ± 7.00.5 ± 1.8
DB Period: Week 364.6 ± 11.74.4 ± 21.3
DB Period: Week 480.5 ± 0.6-0.2 ± 3.4
DB Period: Week 721.2 ± 1.60.1 ± 1.9
DB Period: Week 960.9 ± 1.40.2 ± 1.9
OL Period: Week 483.0 ± 9.70.6 ± 8.8
OL Period: Week 962.7 ± 8.11.9 ± 4.0
OL Period: Week 1444.7 ± 10.70.4 ± 17.1
OL Period: Week 1920.4 ± 9.4-3.6 ± 30.6
SecondaryBrain Magnetic Resonance Imaging Assessment: Change From Baseline in Volume of T1 Hypointense Lesions

Volume of T1 hypointense lesions was measured by MRI scan.

Time frame:
Baseline, DB period: Weeks 24, 36, 48, 72 and 96; OL period: Weeks 48, 96, 144 and 192
Reported as:
Mean · milliliters
Brain Magnetic Resonance Imaging Assessment: Change From Baseline in Volume of T1 Hypointense Lesions
millilitersPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
DB Period: Week 240.3 ± 1.30.0 ± 0.7
DB Period: Week 360.8 ± 1.80.2 ± 0.8
DB Period: Week 480.2 ± 0.40.4 ± 2.9
DB Period: Week 720.1 ± 0.70.1 ± 0.6
DB Period: Week 960.1 ± 0.60.1 ± 0.7
OL Period: Week 480.7 ± 1.90.5 ± 1.4
OL Period: Week 961.0 ± 2.00.6 ± 1.9
OL Period: Week 1442.0 ± 3.01.9 ± 3.4
OL Period: Week 1924.0 ± 5.82.5 ± 5.7
SecondaryBrain Magnetic Resonance Imaging Assessment: Number of New T1 Hypointense Lesions Per MRI Scan

The number of new T1 hypointense lesions were obtained from MRI scans.

Time frame:
Baseline up to Week 192
Reported as:
Number · lesions
Brain Magnetic Resonance Imaging Assessment: Number of New T1 Hypointense Lesions Per MRI Scan
lesionsPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Brain Magnetic Resonance Imaging Assessment: Number of New T1 Hypointense Lesions Per MRI Scan15611910
Statistical analysis
  • Placebo/Teriflunomide vs Teriflunomide/ Teriflunomide · Relative risk ratio: 0.498 · 95% CI 0.296 to 0.836
SecondaryBrain Magnetic Resonance Imaging Assessment: Percentage of Participants Free of New or Enlarged MRI T2-Lesions

Percentage of participants who were free of new or enlarged T2 lesions at Weeks 24, 48, 72, 96, 144 and 192 were reported.

Time frame:
Baseline, Weeks 24, 48, 72, 96, 144 and 192
Reported as:
Number · percentage of participants
Brain Magnetic Resonance Imaging Assessment: Percentage of Participants Free of New or Enlarged MRI T2-Lesions
percentage of participantsPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Week 2486.586.0
Week 4832.725.0
Week 7215.417.0
Week 9615.416.0
Week 14411.514.0
Week 1927.79.0
SecondaryBrain Magnetic Resonance Imaging Assessment: Percent Change From Baseline in Brain Volume at Weeks 24, 36, 48, 72, 96, 144 and 192

Percent change from baseline in brain volume (assessed using MRI scans of the Brain) at Weeks 24, 36, 48,72, 96, 144 and 192 was reported.

Time frame:
Baseline, DB period: Weeks 24, 36, 48, 72 and 96; OL period: Weeks 48, 96, 144 and 192
Reported as:
Mean · percent change
Brain Magnetic Resonance Imaging Assessment: Percent Change From Baseline in Brain Volume at Weeks 24, 36, 48, 72, 96, 144 and 192
percent changePlacebo/TeriflunomideTeriflunomide/ Teriflunomide
DB Period: Week 24-0.3 ± 0.7-0.2 ± 0.7
DB Period: Week 36-0.7 ± 0.7-0.4 ± 1.0
DB Period: Week 48-0.6 ± 1.1-0.5 ± 0.9
DB Period: Week 72-0.9 ± 1.3-0.6 ± 1.1
DB Period: Week 96-0.9 ± 1.3-0.8 ± 1.1
OL Period: Week 48-1.4 ± 1.6-1.1 ± 1.3
OL Period: Week 96-1.8 ± 1.9-1.4 ± 1.6
OL Period: Week 144-3.1 ± 2.8-2.0 ± 1.7
OL Period: Week 192-2.2 ± 1.2-3.0 ± 1.9
SecondaryCognitive Assessment: Change From Baseline in Total Number of Correct Substitutions Measured by Symbol Digit Modalities Test (SDMT) at Weeks 24, 48, 72, 96, 120, 144, 168 and 192

SDMT measures the time to pair abstract symbols with specific numbers. It is a simple substitution task that gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The SDMT score is the number of correct substitution and ranged from 0 (worst outcome) to 110 (best outcome), where higher score indicated better cognitive function.

Time frame:
Baseline, DB period: Weeks 24, 48, 72 and 96; OL period: Weeks 24, 48, 72, 96, 120, 144, 168 and 192
Reported as:
Mean · score on a scale
Cognitive Assessment: Change From Baseline in Total Number of Correct Substitutions Measured by Symbol Digit Modalities Test (SDMT) at Weeks 24, 48, 72, 96, 120, 144, 168 and 192
score on a scalePlacebo/TeriflunomideTeriflunomide/ Teriflunomide
DB Period: Week 245.1 ± 12.04.6 ± 9.1
DB Period: Week 487.3 ± 14.15.7 ± 10.3
DB Period: Week 726.4 ± 12.95.6 ± 11.5
DB Period: Week 968.8 ± 10.78.1 ± 11.1
OL Period: Week 246.3 ± 13.98.3 ± 12.3
OL Period: Week 486.7 ± 13.37.6 ± 13.0
OL Period: Week 728.0 ± 15.59.2 ± 13.0
OL Period: Week 967.6 ± 16.78.0 ± 14.8
OL Period: Week 1203.7 ± 15.97.2 ± 10.3
OL Period: Week 1446.6 ± 14.45.2 ± 13.0
OL Period: Week 1683.5 ± 17.91.7 ± 14.0
OL Period: Week 19212.0-0.3 ± 18.2
SecondaryCognitive Assessment: Change From Baseline in Number of Completed Items Measured by Symbol Digit Modalities Test at Weeks 24, 48, 72, 96, 120, 144, 168 and 192

SDMT measures the time to pair abstract symbols with specific numbers. It is a simple substitution task that gives the examinee 90 seconds to pair specific numbers with given geometric figures as a measure for screening cognitive impairment. The SDMT score is the number of completed items and ranged from 0 (worst outcome) to 110 (best outcome), where higher score indicated better cognitive function.

Time frame:
Baseline, DB period: Weeks 24, 48, 72 and 96; OL period: Weeks 24, 48, 72, 96, 120, 144, 168 and 192
Reported as:
Mean · score on a scale
Cognitive Assessment: Change From Baseline in Number of Completed Items Measured by Symbol Digit Modalities Test at Weeks 24, 48, 72, 96, 120, 144, 168 and 192
score on a scalePlacebo/TeriflunomideTeriflunomide/ Teriflunomide
DB Period: Week 243.8 ± 11.73.6 ± 9.0
DB Period: Week 486.3 ± 13.84.7 ± 10.3
DB Period: Week 725.1 ± 13.44.5 ± 11.4
DB Period: Week 967.1 ± 11.26.9 ± 11.1
OL Period: Week 244.8 ± 13.57.1 ± 12.4
OL Period: Week 485.5 ± 12.86.4 ± 13.0
OL Period: Week 726.4 ± 15.48.1 ± 12.8
OL Period: Week 966.3 ± 16.67.6 ± 12.5
OL Period: Week 1203.7 ± 14.76.3 ± 11.5
OL Period: Week 1444.8 ± 15.13.7 ± 13.4
OL Period: Week 1682.7 ± 15.5-0.3 ± 15.6
OL Period: Week 19212.0-1.5 ± 18.3
SecondaryCognitive Assessment: Change From Baseline in Brief Visuospatial Memory Test-Revised (BVMT-R) Scores at Weeks 96 and 192

The BVMT consists of three trials in which participants must recall shapes by drawing figures on a blank page (response booklet) after being given the opportunity to memorize the figures (given in BMVT-R form) for 10 seconds. BMVT-R form consists of six figures. Points are awarded based on the accuracy of the drawn figure and by correct placement on the blank page. A minimum of 0 to 12 points/scores are awarded per trial, so a participant can score between 0 and 36 points for all three trials (by adding the points/score from each trial), where higher score indicates better outcome.

Time frame:
Baseline, Weeks 96 and 192
Reported as:
Mean · score on a scale
Cognitive Assessment: Change From Baseline in Brief Visuospatial Memory Test-Revised (BVMT-R) Scores at Weeks 96 and 192
score on a scalePlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Baseline23.8 ± 7.224.8 ± 6.4
Change at Week 96-0.8 ± 9.31.6 ± 5.3
Change at Week 1921.0 ± 6.91.2 ± 5.4
SecondaryCognitive Assessment: Change From Baseline in Trail Making Test- Part A (TMT-A) Test Scores (in Seconds) at Week 96 and 192

'Trail Making Test Part A' is a neuropsychological test of visual attention and task switching. The task requires a participant to 'connect-the-dots' of 25 consecutive numbers (1,2, 3, etc.) in sequential order on a sheet of paper or computer screen. The goal of the participant is to finish the test as quickly as possible, and the time taken to complete the test used as the primary performance metric (in seconds). This is a timed test and the number of seconds to complete the task is recorded. Maximum time allowed is 300 seconds. A lower score indicated better cognitive function.

Time frame:
Baseline, Weeks 96 and 192
Reported as:
Mean · seconds
Cognitive Assessment: Change From Baseline in Trail Making Test- Part A (TMT-A) Test Scores (in Seconds) at Week 96 and 192
secondsPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Baseline43.4 ± 24.247.1 ± 23.7
Change at Week 968.4 ± 9.0-3.1 ± 19.5
Change at Week 1926.3 ± 20.7-6.6 ± 17.4
SecondaryCognitive Assessment: Change From Baseline in Trail Making Test B (TMT-B) Test Scores (in Seconds) at Weeks 96 and 192

TMT-B is a cognitive test that gives a measure of various aspects of cognitive performance. It is used to measure cognitive fatigue. The test consisted of 25 circles containing 13 sequential numbers (1 to 13) and 12 sequential letters (A to L) positioned. The test evaluates the time (in seconds) to correctly order letters and numbers in alternate order (1, A, 2, B etc.). Maximum time allowed is 300 seconds, where less time/lower score indicated better cognitive function/performance.

Time frame:
Baseline, Weeks 96 and 192
Reported as:
Mean · seconds
Cognitive Assessment: Change From Baseline in Trail Making Test B (TMT-B) Test Scores (in Seconds) at Weeks 96 and 192
secondsPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Baseline113.8 ± 81.5115.0 ± 44.6
Change at Week 96-19.8 ± 33.7-29.5 ± 56.6
Change at Week 192-37.0 ± 83.3-18.8 ± 37.3
SecondaryCognitive Assessment: Change From Baseline in Beery Visual-motor Integration (BVMI) Scores at Weeks 96 and 192

The Beery VMI is a non-verbal assessment that assessed the extent to which individuals can integrate their visual and motor abilities. The participants were provided with geometric designs ranging from simple line drawings to more complex figures and were asked to copy the designs. The test consisted of 24 figures. One point was scored for each successful copy of drawings and no scoring was given when the participant failed to copy the drawings properly. Each successful copying of drawings was summed up and the total was scored on a scale ranged from 0 to 24, where higher score indicated better visual construction skills/better visual and motor abilities and lower score indicated poor visual construction skills/poor visual and motor abilities.

Time frame:
Baseline, Weeks 96 and 192
Reported as:
Mean · score on a scale
Cognitive Assessment: Change From Baseline in Beery Visual-motor Integration (BVMI) Scores at Weeks 96 and 192
score on a scalePlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Baseline26.1 ± 5.225.9 ± 4.0
Change at Week 960.6 ± 2.4-0.4 ± 4.8
Change at Week 1920.1 ± 5.40.4 ± 2.9
SecondaryCognitive Assessment: Change From Baseline in Wechsler Abbreviated Scale of Intelligence-II (WASI-II) Vocabulary Total Raw Scores at Weeks 96 and 192

The WASI-II: Vocabulary test is a quick estimate of an individual's level of intellectual functioning which comprised of 31 total items that required the participant to orally define 3 images and 28 words presented both orally and visually. Items 1 to 3 rated on a score of 0 or 1, items 4 and 5 rated on a score of 0 or 2, items 6 to 31 rated on a scale of 0 to 2. Each item score was summed up to derive the total score which ranged from 0 (minimum score) to 59 (maximum score), where higher score indicated better level of intellectual functioning/higher level of intelligence.

Time frame:
Baseline, Weeks 96 and 192
Reported as:
Mean · score on a scale
Cognitive Assessment: Change From Baseline in Wechsler Abbreviated Scale of Intelligence-II (WASI-II) Vocabulary Total Raw Scores at Weeks 96 and 192
score on a scalePlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Baseline39.034.3 ± 7.0
Change at Week 965.04.0
Change at Week 1923.05.0
SecondaryCognitive Assessment: Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Letter Fluency Total Correct Raw Score at Weeks 96 and 192

Letter Fluency is a condition measured in the D-KEFS. Participants were asked to name as many words as they can, starting with a specified letter for 60 seconds. The words cannot be names, places, numbers or grammatical variants of previous answers. Repeated answers were not scored as a correct response. There were 3 trials, with 3 different letters. The total number of correct responses was totaled for all 3 trials and a letter fluency score was given. A higher score was considered better. There was no set range as the score depends on how many correct words the participant relays in the given time period.

Time frame:
Baseline, Weeks 96 and 192
Reported as:
Mean · score on a scale
Cognitive Assessment: Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Letter Fluency Total Correct Raw Score at Weeks 96 and 192
score on a scalePlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Baseline32.5 ± 3.521.0 ± 6.0
Change at Week 96-3.04.0 ± 9.9
Change at Week 1925.0-6.5 ± 16.3
SecondaryCognitive Assessment: Change From Baseline in Delis-Kaplan Executive Function System Category Fluency Total Correct Raw Score at Weeks 96 and 192

Category Fluency is a condition measured in the D-KEFS. It measured participant's ability to generate words from three different categories (e.g., fruits, vegetables and animals), within a minute for each category. Total score was number of correct words for each category with no points for repetitions or non-words. Score ranged from 0 to unlimited, where 0 = low score, higher score indicated better performance.

Time frame:
Baseline, Weeks 96 and 192
Reported as:
Mean · score on a scale
Cognitive Assessment: Change From Baseline in Delis-Kaplan Executive Function System Category Fluency Total Correct Raw Score at Weeks 96 and 192
score on a scalePlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Baseline28.0 ± 1.427.5 ± 9.2
Change at Week 966.05.0 ± 5.7
Change at Week 192-2.0-13.5 ± 17.7
SecondaryCognitive Assessment - Selective Reminding Test (SRT): Change From Baseline in Total Number of Words on Delayed Recall at Weeks 96 and 192

SRT is a test to assess verbal learning and memory. During the administration of the SRT only the examiner and the participant should be in the testing room. A list of twelve words was read aloud by the examiner at a rate of one word per two seconds. The participant is asked to recall all twelve words after a 30 minute delay. Only the words that were missed on the preceding trial were given in the consecutive trial. The total score represented a sum score of total 6 trials, therefore the score range was from 0 to 72. The lower the score the worse the outcome, higher score indicated better recall.

Time frame:
Baseline, Weeks 96 and 192
Reported as:
Mean · score on a scale
Cognitive Assessment - Selective Reminding Test (SRT): Change From Baseline in Total Number of Words on Delayed Recall at Weeks 96 and 192
score on a scalePlacebo/TeriflunomideTeriflunomide/ Teriflunomide
Baseline3.5 ± 4.910.0 ± 1.4
Change at Week 961.0-0.5 ± 2.1
Change at Week 1920.00.0
SecondaryDB: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide

Ctrough was defined as the concentration reached by the drug before the next dose administered. Data for this outcome measure was planned to be collected and analyzed separately for each dose of Teriflunomide. PK samples for teriflunomide 3.5 mg were collected during the first 8 weeks but all participants were switched to teriflunomide 7 mg after Week 8. Hence, plasma concentration of teriflunomide 7 mg and 14 mg were reported.

Time frame:
Predose on Week 36
Reported as:
Mean · micrograms per milliliter
DB: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide
micrograms per milliliterTeriflunomide 3.5 mgTeriflunomide 7 mgTeriflunomide 14 mg
DB: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide—53.1 ± 25.367.8 ± 41.7
SecondaryOL: Time to First Confirmed Clinical Relapse

Time to first clinical relapse was defined as duration (in weeks) after enrollment in OL period and first confirmed clinical relapse. Clinical relapses were defined as new or recurrent neurological symptoms not associated with fever or infection, lasted at least 24 hours and accompanied by new objective neurological findings upon neurological examination and documented by standardized, quantified FSSs which included 8 items and items were rated on different scales: brain stem, cerebellar \& cerebral functions rated on scale of 0 to 5; visual, pyramidal, sensory and bowel/bladder rated on scale of 0 to 6 and ambulation on scale of 0 to 12 where higher score in each scale indicated worsened neurological function. Confirmed clinical relapse were reviewed and confirmed by independent RAP. Participant without confirmed clinical relapse, was considered as clinical relapse free until end of Week 192.

Time frame:
Baseline up to Week 192
Reported as:
Median · weeks
OL: Time to First Confirmed Clinical Relapse
weeksPlacebo/TeriflunomideTeriflunomide/ Teriflunomide
OL: Time to First Confirmed Clinical Relapse95.86 (0.6 to 176.0)96.00 (1.0 to 183.4)
Statistical analysis
  • Placebo/Teriflunomide vs Teriflunomide/ Teriflunomide · Hazard ratio (hr): 0.693 · 95% CI 0.37 to 1.296Hazard ratio estimated using a Cox proportional-hazards model using treatment group, region, pubertal status, age, and number of relapses in the year prior to randomisation as covariates and with robust variance estimation.
SecondaryOL: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide

Ctrough was defined as the concentration reached by the drug before the next dose is administered. Data for this outcome measure was planned to be collected and analyzed separately for each dose of teriflunomide. PK samples for teriflunomide 3.5 mg were collected during the first 8 weeks but all participants were switched to teriflunomide 7 mg after Week 8. Hence, plasma concentration of teriflunomide 7 mg and 14 mg were reported.

Time frame:
Pre-dose at Week 36
Reported as:
Mean · micrograms per milliliter
OL: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide
micrograms per milliliterPlacebo / Teriflunomide 3.5 mgPlacebo / Teriflunomide 7 mgPlacebo / Teriflunomide 14 mgTeriflunomide / Teriflunomide 3.5 mgTeriflunomide / Teriflunomide 7 mgTeriflunomide / Teriflunomide 14 mg
OL: Pharmacokinetics: Steady-state Trough Concentration (Ctrough) of Teriflunomide—45.8 ± 35.350.4 ± 23.8—33.7 ± 10.763.6 ± 35.5

Adverse events

Collected over Treatment-emergent adverse events (TEAEs), treatment-emergent serious AEs and deaths were collected from first dose of study drug (Day 1) up to 96 weeks (for DB period arms), first dose of study drug in OL period (Week 97) up to Week 192 (for OL period arms) and first dose of study drug in extension period (Week 193) up to Week 492 (for extension period arm).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Treatment Period: Placebo0/57 (0%)6/57 (10.5%)42/57 (73.7%)
Double-Blind Treatment Period: Teriflunomide0/109 (0%)12/109 (11%)89/109 (81.7%)
Open-Label Treatment Period: Placebo/Teriflunomide0/52 (0%)15/52 (28.8%)40/52 (76.9%)
Open-Label Treatment Period: Teriflunomide/Teriflunomide0/100 (0%)14/100 (14%)72/100 (72%)
Extension Period/Teriflunomide0/27 (0%)8/27 (29.6%)18/27 (66.7%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventDouble-Blind Treatment Period: PlaceboDouble-Blind Treatment Period: TeriflunomideOpen-Label Treatment Period: Placebo/TeriflunomideOpen-Label Treatment Period: Teriflunomide/TeriflunomideExtension Period/Teriflunomide
Alanine Aminotransferase IncreasedInvestigations0/571/1092/520/1000/27
AsthmaRespiratory, thoracic and mediastinal disorders1/570/1092/520/1000/27
BradycardiaCardiac disorders0/570/1090/520/1001/27
Sudden Hearing LossEar and labyrinth disorders0/570/1090/520/1001/27
Complicated AppendicitisInfections and infestations0/570/1090/520/1001/27
Salpingo-OophoritisInfections and infestations0/570/1090/520/1001/27
Multiple Sclerosis RelapseNervous system disorders0/570/1090/520/1001/27
Partial SeizuresNervous system disorders0/570/1090/520/1001/27
SyncopeNervous system disorders1/572/1090/521/1001/27
Transient Ischaemic AttackNervous system disorders0/570/1090/520/1001/27
Most frequent other events
Showing 10 of 113
Most frequent other events
EventDouble-Blind Treatment Period: PlaceboDouble-Blind Treatment Period: TeriflunomideOpen-Label Treatment Period: Placebo/TeriflunomideOpen-Label Treatment Period: Teriflunomide/TeriflunomideExtension Period/Teriflunomide
NasopharyngitisInfections and infestations5/5728/1098/5220/1004/27
HeadacheNervous system disorders13/5718/1097/5214/1001/27
Upper Respiratory Tract InfectionInfections and infestations6/5724/1097/5222/1006/27
AlopeciaSkin and subcutaneous tissue disorders7/5724/1099/5210/1001/27
DiarrhoeaGastrointestinal disorders4/578/1096/527/1001/27
Alanine Aminotransferase IncreasedInvestigations1/572/1096/523/1002/27
DizzinessNervous system disorders4/579/1096/522/1000/27
Covid-19Infections and infestations0/570/1090/520/1003/27
Accidental OverdoseInjury, poisoning and procedural complications4/575/1092/5210/1003/27
Neutrophil Count DecreasedInvestigations0/573/1091/522/1003/27

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo/TeriflunomideTeriflunomide/TeriflunomideTotal
Mean14.7 ± 2.114.6 ± 2.014.6 ± 2.0
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/TeriflunomideTeriflunomide/TeriflunomideTotal
Female3972111
Male183755
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo/TeriflunomideTeriflunomide/TeriflunomideTotal
Race — Caucasian/White4275117
Race — Black145
Race — Asian/Oriental122537
Race — Other257
07

Study locations

57 sites
  • North Central Neurology Associates, PC Site Number : 840003
    Cullman, Alabama 35058, United States
  • Axiom Clinical Research of Florida Site Number : 840012
    Tampa, Florida 33609-4052, United States
  • Massachusetts General Hospital Site Number : 840002
    Boston, Massachusetts 02114, United States
  • Raleigh Neurology Associates Site Number : 840004
    Raleigh, North Carolina 27607, United States
  • Investigational Site Number : 056002
    Gent, 9000, Belgium
  • Investigational Site Number : 056001
    Leuven, 3000, Belgium
  • Investigational Site Number : 100001
    Sofia, 1113, Bulgaria
  • Investigational Site Number : 124001
    Calgary, Alberta T3B 6A8, Canada
  • Investigational Site Number : 156001
    Beijing, 100034, China
  • Investigational Site Number : 156002
    Beijing, 100045, China
  • Investigational Site Number : 156010
    Beijing, 100730, China
  • Investigational Site Number : 156006
    Changchun, 130021, China
  • Investigational Site Number : 156007
    Changsha, 410011, China
  • Investigational Site Number : 156008
    Chengdu, 610041, China
  • Investigational Site Number : 156005
    Chongqing, 400014, China
  • Investigational Site Number : 156012
    Guangzhou, 510630, China
  • Investigational Site Number : 156003
    Shanghai, 200092, China
  • Investigational Site Number : 156004
    Shanghai, 201102, China
  • Investigational Site Number : 156011
    Shijiazhuang, 050000, China
  • Investigational Site Number : 156009
    Taiyuan, 030001, China
  • Investigational Site Number : 233001
    Tallinn, 10617, Estonia
  • Investigational Site Number : 250001
    Le Kremlin Bicetre, 94270, France
  • Investigational Site Number : 250002
    Lyon Cedex 03, 69394, France
  • Investigational Site Number : 250003
    Rennes Cedex, 35033, France
  • Investigational Site Number : 250005
    Toulouse, 31059, France
  • Investigational Site Number : 300002
    Athens, 115 27, Greece
  • Investigational Site Number : 300001
    Thessaloniki, 54642, Greece
  • Investigational Site Number : 376001
    Jerusalem, 91120, Israel
  • Investigational Site Number : 376003
    Tel HaShomer, 52621, Israel
  • Investigational Site Number : 422001
    Beirut, 11-0236, Lebanon
  • Investigational Site Number : 440001
    Kaunas, 50161, Lithuania
  • Investigational Site Number : 504004
    FES, Morocco
  • Investigational Site Number : 504005
    Marrakech, 40000, Morocco
  • Investigational Site Number : 528001
    Rotterdam, 3015 CN, Netherlands
  • Investigational Site Number : 807001
    Skopje, 1000, North Macedonia
  • Investigational Site Number : 807002
    Stip, 2000, North Macedonia
  • Investigational Site Number : 620001
    Coimbra, 3000-075, Portugal
  • Investigational Site Number : 643001
    Moscow, 127566, Russian Federation
  • Investigational Site Number : 643003
    Nizhny Novgorod, 603155, Russian Federation
  • Investigational Site Number : 643004
    Novosibirsk, 630087, Russian Federation
  • Investigational Site Number : 643005
    Saint-Petersburg, 197022, Russian Federation
  • Investigational Site Number : 643002
    Saint-Petersburg, 197110, Russian Federation
  • Investigational Site Number : 688002
    Belgrade, 11000, Serbia
  • Investigational Site Number : 724002
    Murcia, 30120, Spain
  • Investigational Site Number : 788001
    La Manouba, 2020, Tunisia
  • Investigational Site Number : 788002
    Sfax, 3029, Tunisia
  • Investigational Site Number : 788004
    Sfax, 3029, Tunisia
  • Investigational Site Number : 792002
    Ankara, 06100, Turkey
  • Investigational Site Number : 792001
    Ankara, 06500, Turkey
  • Investigational Site Number : 792006
    Istanbul, 34390, Turkey
  • Investigational Site Number : 792003
    Istanbul, 34688, Turkey
  • Investigational Site Number : 792008
    Izmir, 35210, Turkey
  • Investigational Site Number : 792007
    İzmir, Turkey
  • Investigational Site Number : 804001
    Kharkiv, 61068, Ukraine
  • Investigational Site Number : 804002
    Kharkiv, 61068, Ukraine
  • Investigational Site Number : 826001
    London, London, City Of SE1 7EH, United Kingdom
  • Investigational Site Number : 826003
    Birmingham, B4 6NH, United Kingdom
08

References and documents

Publications

  • Chitnis T, Banwell B, Kappos L, Arnold DL, Gucuyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M; TERIKIDS Investigators. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021 Dec;20(12):1001-1011. doi: 10.1016/S1474-4422(21)00364-1. PubMed 34800398 ↗

Study documents

  • Study protocol · Dec 10, 2020
  • Statistical analysis plan · Jun 28, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Registry details

Key details

Study ID
NCT02201108
Lead sponsor
Genzyme, a Sanofi Company
Responsible party
Sponsor
First posted
Jul 25, 2014
Start date
Jul 16, 2014
Primary completion
Oct 25, 2019
Completion
Jul 29, 2024
Results posted
Nov 30, 2020
Last update
Feb 6, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion